Subscribe to Biological Therapies in Psychiatry -  Choose your plan >
IN THIS MONTH'S ISSUE:
April 2014

Zinc and Depression
Preliminary evidence suggests that zinc deficiency may be associated with depression.

Antidepressant-Induced Sexual Dysfunction: Exercise as an Antidote?
In women experiencing antidepressant-induced sexual dysfunction, exercise appears to improve sexual desire, global sexual function, and orgasm function.

Varenicline in Patients with Depression History
In a study of subjects with past or current depression, varenicline (Chantix) improved cigarette smoking abstinence rates without producing neuropsychiatric adverse effects.

Fluoxetine and the QTc Interval
QTc prolongation can occur in association with fluoxetine (Prozac and others) in patients with a personal or family history of the condition or predisposing risk factors, and in those taking certain other medications.

In Brief
Auditory Training via Computers Improves Cognitive Function in Schizophrenia; Salivary Cortisol Levels Predict Risk for Depression in Young Males

Antipsychotic Strategies in First-Episode Schizophrenia
A recent study found little benefit for high-dose antipsychotic treatment in patients with a first episode of schizophrenia who were nonresponsive to recommended doses.

A Message from Alan J. Gelenberg, M.D.

When I first started writing BTP in the 1970s, it was to bridge the gap between new knowledge in our field and its application to patient care. Over the decades since, the need for this bridge has become even greater. Neuroscience rockets forward. Psychiatrists and other clinicians have a broader array of treatments for patients with mental disorders than we even dreamed of back then. But we have less time to spend with patients and less time to keep up with developments that affect treatment decisions. Our medications, and those prescribed by colleagues in other specialties, are more varied, complex, and prone to interactions. What were formerly crisp boundaries between major psychopharmacologic categories are now murky.

This makes the modern practice of psychiatry challenging—but also fun and promising. With the expanding armamentarium of treatment options comes enhanced ability to alleviate suffering. The mission of BTP remains constant, even while the field grows. We are still here to bridge the gap, to make science applicable and relevant, and to help you in your day-to-day work relieve distress and improve function in patients' lives.